Is non-celiac gluten sensitivity a real condition?

Gluten is a protein complex found in wheat, barley, and rye. In celiac disease, an autoimmune response to gliadin (a gluten fraction) causes villous atrophy in the small intestine — this is detectable by biopsy and blood tests. NCGS appears to operate differently. The immune response is innate rather than adaptive, meaning it does not involve the same antibody production, and intestinal architecture remains intact on biopsy¹.

The Zonulin and Leaky Gut Connection

Even in people without celiac disease, gliadin exposure triggers the release of zonulin, a protein that regulates intestinal tight junctions — the seals between intestinal cells. When zonulin rises, these junctions loosen, increasing intestinal permeability^4,5. In NCGS, this response is more transient than in celiac disease but may still allow bacterial fragments and undigested proteins to cross into the bloodstream, activating immune cells.

Researchers from Columbia University found that individuals reporting wheat sensitivity (without celiac disease) had significantly elevated blood markers of intestinal cell damage (FABP2) and systemic immune activation, including raised levels of LPS-binding protein and anti-bacterial antibodies⁶. These markers improved significantly after adopting a wheat-free diet.

Symptoms Beyond the Gut

The Italian multicenter survey by Volta et al. found that NCGS presents with a distinctive combination of gastrointestinal symptoms (abdominal pain, bloating, diarrhea, constipation) and systemic complaints including fatigue, headache, foggy mind, joint and muscle pain, numbness in the limbs, skin rash, depression, and anxiety³. The female-to-male ratio was 5.4:1, suggesting hormonal or immunological factors in susceptibility.

Diagnosing NCGS

There is no biomarker test for NCGS. Diagnosis requires:

1. Ruling out celiac disease (normal IgA anti-tTG, normal biopsy)
2. Ruling out wheat allergy (negative IgE testing)
3. Improvement on a gluten-free diet
4. Confirmation by blinded gluten rechallenge if needed

Some patients test positive for anti-gliadin IgA antibodies (not to be confused with the celiac-specific anti-tTG), which may act as a useful supportive marker, but this is not required for diagnosis².

The FODMAP Question

A complicating factor in NCGS research is that wheat contains fructans, a type of FODMAP (fermentable carbohydrate) that also causes digestive distress in sensitive individuals. Some double-blind rechallenge studies suggest that at least a portion of people who attribute symptoms to gluten may actually be reacting to fructans. Current consensus is that both mechanisms likely operate — some people are reacting to gliadin proteins, others to FODMAPs, and some to both^1,2.

Management

For those with confirmed NCGS, a gluten-free diet is the primary intervention. Many find that symptoms resolve within days to weeks of eliminating wheat, barley, and rye. Some individuals tolerate ancient grains like einkorn or emmer, or sourdough fermentation of wheat (which partially breaks down gliadin), though this is highly individual. See the Leaky Gut page for additional strategies to support intestinal barrier function.

Classification and Prevalence

Sapone et al. (2012) provided the first formal consensus framework recognizing NCGS as a distinct condition within the spectrum of gluten-related disorders, alongside celiac disease and wheat allergy¹. This consensus paper, authored by an international group including Fasano and Catassi, established the current terminology and diagnostic approach. The authors noted that NCGS was originally described in the 1980s, fell into obscurity, and was only then being rediscovered.

Catassi et al. (2013) provided a thorough review of the emerging field, noting that NCGS had been documented in peer-reviewed literature at an accelerating rate and that population prevalence estimates ranged widely — from 0.5% to 13% — due to the absence of a validated biomarker². The authors described the symptom profile, proposed pathogenic mechanisms, and called for double-blind placebo-controlled rechallenge as the gold standard for diagnosis.

Epidemiology: The Italian Survey

The most detailed epidemiological snapshot of NCGS comes from Volta et al. (2014), who surveyed 486 cases identified across 38 Italian gastroenterology and allergy centers over 12 months³. Key findings:

• Prevalence ratio relative to celiac disease was approximately 1:7.6 (about 1 NCGS case for every 7.6 celiac cases seen in these specialist centers)
• Mean age at diagnosis: 38 years
• Female-to-male ratio: 5.4:1
• Most common gastrointestinal symptoms: abdominal pain (68%), bloating (40%), diarrhea (38%)
• Most common extraintestinal symptoms: tiredness (64%), headache (54%), foggy mind (38%), anxiety (39%), joint and muscle pain (31%), numbness in limbs (32%)
• 64% had a family history of celiac disease, wheat allergy, or NCGS — suggesting a genetic predisposition
• Anti-gliadin IgA was positive in 25% of patients; anti-gliadin IgG in 18%

Biological Mechanism: Zonulin and Gut Permeability

Drago et al. (2006) from the Fasano laboratory demonstrated that gliadin triggers zonulin release and increases intestinal permeability in both celiac and non-celiac intestinal biopsies, as well as in intestinal cell lines⁴. The key mechanistic difference: celiac biopsies showed a sustained, high-magnitude permeability increase, while non-celiac biopsies showed a more limited and transient response — but a response nonetheless. This established that gliadin-induced permeability changes are not exclusive to celiac disease.

Lammers et al. (2008) identified the receptor responsible: gliadin binds to the chemokine receptor CXCR3 on enterocytes, triggering MyD88-dependent zonulin release and tight junction opening⁵. CXCR3 expression was elevated in active celiac disease biopsies and normalized with a gluten-free diet. Importantly, gliadin-induced permeability was absent in CXCR3-knockout mice, confirming this as a central pathway.

Systemic Immune Activation in NCGS

Uhde et al. (2016) at Columbia University conducted the most rigorous investigation to date of non-celiac wheat sensitivity using objective biological markers⁶. They compared 80 patients with self-reported wheat sensitivity (confirmed non-celiac, non-allergic) to healthy controls and active celiac disease patients.

Key findings in the wheat-sensitive group:

• Significantly elevated serum FABP2 (fatty acid-binding protein 2), a marker of intestinal epithelial cell damage
• Significantly elevated soluble CD14 and LPS-binding protein, indicating bacterial translocation and systemic immune activation
• Elevated IgG and IgM antibodies against flagellin and LPS — bacterial components that normally remain in the gut lumen
• All markers showed statistically significant improvement toward normal in a subgroup who maintained a wheat-free diet for six months

These findings provide the strongest biological evidence to date that NCGS involves measurable intestinal cell damage and systemic immune activation — not merely a functional or psychosomatic response.

Limitations and Open Questions

The evidence base for NCGS remains limited by the absence of a validated biomarker, making population prevalence estimates unreliable and clinical diagnosis dependent on exclusion and dietary response. Several double-blind rechallenge trials have produced mixed results, and the overlap with FODMAP sensitivity makes it difficult to isolate gluten as the causative agent in many individuals. Larger randomized trials are needed. Nonetheless, the biological plausibility has strengthened considerably since Uhde et al. (2016), and clinical recognition is growing.